| Dr Fernando Lopez, MD | |
|
1097 Sw 42nd Ave Fl 3, Miami, FL 33134-2639 | |
| (305) 442-2020 | |
| Not Available |
| Full Name | Dr Fernando Lopez |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 29 Years |
| Location | 1097 Sw 42nd Ave Fl 3, Miami, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013941657 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 036104977 (Illinois) | Secondary |
| 207W00000X | Ophthalmology | ME80092 (Florida) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Aran Eye Associates Pa | 4486615770 | 23 |
News Archive
The Norwegian research council model is the result of an innovative reform carried out in the 1990s. Now a public evaluation of the Research Council's activities is in the works to find out whether the model is functioning as intended.
We were able to show that one small domain of the polymerase, the part that is essential for entry of a piece of the polymerase into the cell nucleus, changes its conformation to allow it to interact with the transporter protein than takes it into the nucleus.
Uroplasty, Inc. highlighted results from a two-year, multicenter clinical study of Macroplastique that will be published in the April 2010 print edition of The Journal of Urology(R). The 24-month study evaluated the durability of Macroplastique for stress urinary incontinence in women with previously documented success at 12 months. Substantial, durable results were sustained during 2 years with 84% of patients maintaining significant improvement from their 12-month assessment. Additionally, 67% of the patients implanted with Macroplastique were dry at the 24-month follow-up visit.
Mersana Therapeutics, a platform-based cancer therapeutics company, announced today additional preliminary results from an ongoing Phase 1 study of its lead development candidate, XMT-1001, in patients with advanced solid tumors.
EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced that Canaan Partners and Radius Ventures co-led a $30 Million Series F financing designed to support the company through profitability.
› Verified 7 days ago
| Entity Name | Aran Eye Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295832582 PECOS PAC ID: 4486615770 Enrollment ID: O20041020000746 |
News Archive
The Norwegian research council model is the result of an innovative reform carried out in the 1990s. Now a public evaluation of the Research Council's activities is in the works to find out whether the model is functioning as intended.
We were able to show that one small domain of the polymerase, the part that is essential for entry of a piece of the polymerase into the cell nucleus, changes its conformation to allow it to interact with the transporter protein than takes it into the nucleus.
Uroplasty, Inc. highlighted results from a two-year, multicenter clinical study of Macroplastique that will be published in the April 2010 print edition of The Journal of Urology(R). The 24-month study evaluated the durability of Macroplastique for stress urinary incontinence in women with previously documented success at 12 months. Substantial, durable results were sustained during 2 years with 84% of patients maintaining significant improvement from their 12-month assessment. Additionally, 67% of the patients implanted with Macroplastique were dry at the 24-month follow-up visit.
Mersana Therapeutics, a platform-based cancer therapeutics company, announced today additional preliminary results from an ongoing Phase 1 study of its lead development candidate, XMT-1001, in patients with advanced solid tumors.
EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced that Canaan Partners and Radius Ventures co-led a $30 Million Series F financing designed to support the company through profitability.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Fernando Lopez, MD 951 Sw 42nd Ave, Ste 204, Miami, FL 33134-2616 Ph: (305) 442-2020 | Dr Fernando Lopez, MD 1097 Sw 42nd Ave Fl 3, Miami, FL 33134-2639 Ph: (305) 442-2020 |
News Archive
The Norwegian research council model is the result of an innovative reform carried out in the 1990s. Now a public evaluation of the Research Council's activities is in the works to find out whether the model is functioning as intended.
We were able to show that one small domain of the polymerase, the part that is essential for entry of a piece of the polymerase into the cell nucleus, changes its conformation to allow it to interact with the transporter protein than takes it into the nucleus.
Uroplasty, Inc. highlighted results from a two-year, multicenter clinical study of Macroplastique that will be published in the April 2010 print edition of The Journal of Urology(R). The 24-month study evaluated the durability of Macroplastique for stress urinary incontinence in women with previously documented success at 12 months. Substantial, durable results were sustained during 2 years with 84% of patients maintaining significant improvement from their 12-month assessment. Additionally, 67% of the patients implanted with Macroplastique were dry at the 24-month follow-up visit.
Mersana Therapeutics, a platform-based cancer therapeutics company, announced today additional preliminary results from an ongoing Phase 1 study of its lead development candidate, XMT-1001, in patients with advanced solid tumors.
EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced that Canaan Partners and Radius Ventures co-led a $30 Million Series F financing designed to support the company through profitability.
› Verified 7 days ago
Efrem D Mandelcorn, ND Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 900 Nw 17th St, Miami, FL 33136 Phone: 305-326-6000 Fax: 605-547-3713 | |
Zelia Maria Correa, MD, PHD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 900 Nw 17th St, Miami, FL 33136 Phone: 305-326-6000 | |
Dr. Kendall E Donaldson, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 900 Nw 17th Ave, Miami, FL 33101 Phone: 305-326-6031 Fax: 305-243-8470 | |
Dr. Richard K Forster, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 900 Nw 17th Ave, Box 016960 M851, Miami, FL 33101 Phone: 305-326-6031 Fax: 305-243-8470 | |
Ta Chen Peter Chang, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 900 Nw 17th St, Miami, FL 33136 Phone: 305-243-2020 Fax: 305-326-6306 | |
Lily Zhang, Ophthalmology Medicare: Medicare Enrolled Practice Location: 1611 Nw 12th Ave, Miami, FL 33136 Phone: 305-326-6391 |